"Merck on Thursday announced that its blockbuster PD-1 inhibitor Keytruda (pembrolizumab) fell short of its dual primary endpoints in the Phase III KEYLYNK-006 trial, unable to significantly improve survival outcomes in specific patients with metastatic non-squamous non-small cell lung cancer." the article says.
https://www.biospace.com/article/merck-s-keytruda-continues-losing-streak-in-nsclc-with-phase-iii-flop/?utm_campaign=Daily%20Social%20%7C%20News&utm_content=286824601&utm_medium=social&utm_source=linkedin&hss_channel=lcp-424124
bisantrene could be Keytruda's saviour...
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-1660
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.55 |
Change
-0.015(0.96%) |
Mkt cap ! $257.8M |
Open | High | Low | Value | Volume |
$1.59 | $1.59 | $1.51 | $189.1K | 121.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $1.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.55 | 999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 1.515 |
2 | 3484 | 1.510 |
3 | 3666 | 1.500 |
1 | 1750 | 1.485 |
1 | 1784 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.550 | 999 | 1 |
1.580 | 5252 | 3 |
1.590 | 7591 | 2 |
1.595 | 591 | 1 |
1.620 | 13999 | 1 |
Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.52 |
  |
Change
-0.015 ( 2.88 %) |
|||
Open | High | Low | Volume | ||
$1.55 | $1.58 | $1.51 | 7772 | ||
Last updated 15.59pm 17/05/2024 ? |
Featured News
RAC (ASX) Chart |